CLINICAL CONSIDERATIONS

immunotherapy_is_tumor-specific_720p

SPECIFIC

Immunotherapy builds a population of immune cells over time that specifically target cancer cells1-4

Learn more by watching Immunotherapy Is Tumor-Specific (2:03)

immunotherapy_is_designed_to_support_immune_system_720p

ADAPTABLE

The activated immune system adapts as cancer mutates, enabling it to recognize new tumor antigens2-3,5-6

Learn more by watching Immunotherapy Is Adaptable (2:42)

immunotherapy_empowers_a_durable_immune_response_720p

DURABLE

The immune system has memory and remains primed to stimulate a tumor-specific response1,7

Learn more by watching Immunotherapy is Durable (2:18)

Patients may respond differently to immunotherapy than to traditional cancer agents.

  • Immunotherapy targets the tumor over time, so although response may occur more slowly than with traditional cytotoxic therapies, the immune effect is potentially adaptable and durable2-4

  • RECIST criteria were designed to assess response to traditional cytotoxic agents so they are not as relevant for immunotherapy, which works differently2-4

immunotherapy_fights_cancer_720p

Learn more by watching Immunotherapy Works Differently (2:44)

bdySection3TumorGraphic

REFERENCES

  1. Murphy K, Travers P, Walport M, eds. Janeway’s Immunobiology. 7th ed. Garland Science, Taylor & Frances Group, LLC. New York, NY: 2008.
  2. Sharma P, Wagner K, Wolchok JD, Allison JP. Nat Rev Cancer. 2011;11:805-812.
  3. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. CA Cancer J Clin. 2012;62(5):309-335.
  4. Mellman I, Coukos G, Dranoff G. Nature. 2011;480:480-489.
  5. Ribas A, Butterfield LH, Glaspy JA, Economou JS. J Clin Oncol. 2003;21:2415-2432.
  6. Disis ML, Strickler JH, Wallace D, et al. J Clin Oncol. 2008;26(suppl):(May 20 suppl; abstr 3015).
  7. Klebanoff CA, Gattinoni L, Restifo NP. Immunol Rev. 2006;211:214-224.